

## **Corporate Responsibility Materiality Assessment**

In 2023, we conducted our first CR materiality assessment to identify and prioritize corporate responsibility and environment, social and governance (ESG) topics that could impact our business success and matter most to our stakeholders. This process considered both internal and external perspectives and included:

- Interviews with internal business leaders and experts to rank CR topics based on their importance to our business and their ability to impact our stakeholders
- A prioritization session with the CR Committee to develop our materiality matrix, which was finalized following endorsement by the CEO and Board of Directors
- Review of best practice from ESG raters and reporting standards, and peer benchmarking to identify an initial list of important CR topics impacting our business
- Assessment of external stakeholder priorities including investors, ratings and rankings agencies, patient advocacy organizations, community groups and other stakeholders

All material topics are important, and we are committed to addressing these issues proactively. Our materiality matrix helps us focus our efforts, while still ensuring visibility and action on all material issues. Prioritizing these topics helps us allocate resources and communicate more effectively with both internal and external audiences on the issues and topics that matter most to our business and our stakeholders.

## **Corporate Responsibility Materiality Matrix** Topics are listed in alphabetical order, not importance Higher Priority Clinical Trial Practices Continuous Therapeutic Innovation Data Security and Privacy Climate Risks and Environmental Management Diversity, Equity and Inclusion Importance to stakeholders Energy Management Ethics and Compliance Health Equity and Outcomes Patient Advocacy and Engagement Product Accessibility Product Quality and Patient Safety Talent Attraction, Engagement and Development Community Engagement and Corporate Giving Corporate Governance and Leadership Human Rights Employee Health and Safety Responsible and Sustainable Supply Chain Responsible Sales and Marketing Waste Management Risk and Crisis Management Water Management Priority Importance to the business Higher Priority

## **Materiality Definitions**

ТОРІС	DEFINITION
Clinical Trial Practices	Ensure transparent and ethical clinical trials, and diversity and accessibility for trial subjects
Continuous Therapeutic Innovation	Research and develop new therapeutic products and services for unmet need (first-in-class, best-in-class)
Climate Risks and Environmental Management	Policies and programs to ensure regulatory compliance, minimize resource usage, reduce carbon emissions and understand and mitigate climate change-related risks
Community Engagement and Corporate Giving	Engage community stakeholders, support philanthropic efforts and support employee volunteering
Corporate Governance and Leadership	Executive leadership and Board oversight of business priorities
Data Security and Privacy	Policies and programs to protect patient data and the company against cybersecurity risks
Diversity, Equity and Inclusion	Programs and mechanisms to promote a diverse, equitable and inclusive workplace
Employee Health and Safety	Policies and programs to ensure regulatory compliance and minimize and prevent accidents
Energy Management	Efforts to minimize energy use, as well as adopt renewable energy use
Ethics and Compliance	Policies and programs to ensure business ethics and regulatory and healthcare compliance
Health Equity and Outcomes	Work to address disparities in access to health care, such as poverty, racial discrimination and other social determinants of health, to increase positive outcomes across populations
Human Rights	Policies and programs to protect human rights throughout operations
Patient Advocacy and Engagement	Mechanisms to engage with patients to identify and understand their needs
Product Accessibility	Ensure patient access to medicines and products (access to medicines) and fair pricing
Product Quality and Patient Safety	Ensure product quality, safety and efficacy, as well as regulatory and pharmacovigilance compliance throughout product lifecycle
Responsible Sales and Marketing	Programs to ensure product sales and marketing adheres to ethical and regulatory standards

Responsible and Sustainable Supply Chain	Ensure suppliers meet social and environmental expectations and standards; efforts to engage diverse and inclusive suppliers
Risk and Crisis Management	Programs and systems in place to identify emerging risks that could have an adverse effect on the company
Talent Attraction, Engagement and Development	Ensure hiring, engagement and retention of top talent and provide the technical and leadership training to develop and advance employees
Water Management	Efforts to minimize water use
Waste Management	Efforts to minimize hazardous and non-hazardous waste, promote recycling, and reuse

## **Definitions of Materiality**

The discussion of topics included in this report and our other corporate responsibility and sustainability disclosures should not be read as implying that such topics are "material" in the context of the U.S. federal securities laws, Delaware General Corporation Law or any other regulatory framework, even where we use words such as "material" or "materiality. Our approach to sustainability and other corporate responsibility disclosures is informed by sustainability reporting frameworks, that involve broader definitions of materiality than used for purposes of our compliance with SEC disclosure obligations. As a result, "materiality" for purposes of our corporate responsibility reporting includes impacts on communities, the environment and stakeholders such as employees, patients and suppliers, and the inclusion of topics in such reporting, even when described as "material," does not indicate that such topics are material to the Company's business, operations or financial condition.